Ovid Therapeutics (OVID) EBIT Margin (2020 - 2025)
Ovid Therapeutics' (OVID) quarterly EBIT Margin came in at 1712.12% in Q4 2025, up 1239578.0% YoY from N/an in Q4 2024, and up 81.95% on a QoQ basis from 9487.12% in Q3 2025.
Ovid Therapeutics (OVID) EBIT Margin (2020 - 2025) Analysis & Trends
Ovid Therapeutics (OVID) has 6 years of EBIT Margin data on file, last reported at 1712.12% in Q4 2025.
- Quarterly EBIT Margin rose 1239578.0% year-over-year to 1712.12% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 670.25% (up 973395.0% YoY) and the FY2025 annual result came in at 585.2%, up 1034854.0% from the prior year.
- EBIT Margin climbed to 1712.12% in Q4 2025, from 9487.12% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 84.73% in Q1 2021 to a low of 115329.27% in Q3 2022.
- A 5-year average of 17160.75% and a median of 11402.01% in 2023 frame the typical range for EBIT Margin.
- The widest YoY moves for EBIT Margin: up 10429349 bps in 2023, down 2143817 bps in 2023.
- Tracing OVID's EBIT Margin over 5 years: stood at 84.73% in 2021, then plunged by 31144 bps to 26302.75% in 2022, then jumped by 51 bps to 12808.45% in 2023, then declined by 10 bps to 14107.89% in 2024, then jumped by 88 bps to 1712.12% in 2025.
- The last three EBIT Margin figures came in at 1712.12% (Q4 2025), 9487.12% (Q3 2025), and 80.88% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,712.12% |
| Sep 30, 2025 | -9,487.12% |
| Jun 30, 2025 | -80.88% |
| Mar 31, 2025 | -9,653.85% |
| Dec 31, 2024 | -14,107.89% |
| Sep 30, 2024 | -7,645.09% |
| Jun 30, 2024 | -12,140.24% |
| Mar 31, 2024 | -11,768.24% |
| Dec 31, 2023 | -12,808.45% |
| Sep 30, 2023 | -11,035.78% |
| Jun 30, 2023 | -18,896.00% |
| Mar 31, 2023 | -22,563.64% |
| Dec 31, 2022 | -26,302.75% |
| Sep 30, 2022 | -115,329.27% |
| Mar 31, 2022 | -1,125.47% |
| Mar 31, 2021 | 84.73% |
| Dec 31, 2020 | -378.58% |
| Sep 30, 2020 | -237.25% |